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Background: Pre-procedural administration of statins has been found to be associated
with reduced peri-procedural myocardial injury and infarction.
Aim: The aim of the present study was to evaluate the effect of pre-procedural single
high loading dose (40 mg) of rosuvastatin on the primary end-points of all cause
mortality and composite of death or myocardial infarction from cardiovascular (CV)
causes, target vessel revascularization (TVR), or stroke.
Methods: Two hundred ninety nine statin-naive patients with stable ischemic heart
disease (SIHD) and de novo lesions appropriate for PCI were randomized to rosu-
vastatin-treatment (n¼153) and to no-treatment (n¼146) groups. A 40 mg loading
dose of rosuvastatin was administrated 24 h before the PCI. Four-year follow-up
period was planned (long-term follow-up of previously published study).
Results: A total of 290 (97%) patients (147 rosuvastatin and 143 no-treatment)
completed the study. The median age was 62 years. Male was 70% and 18% of patients
had diabetes and 43% had hypertension. Previous MI and PCI/CABG history were
present in 27% and 39% of patients, respectively. The primary end-point of all cause
death and composite of death or myocardial infarction from CV causes, TVR, or stroke
was lower in the rosuvastatin group compared with the no-treatment group (10.2% vs.
22.4%, p¼0.005), driven by a reduction in TVR (6.1% vs. 13.3%, p¼0.039).
Conclusion: Among patients with SIHD undergoing PCI, pre-procedural adminis-
tration of single high loading dose of rosuvastatin was associated with a reduction in
major adverse cardiac and cerebrovascular events (MACCE) at 4 years, driven
primarily by a reduction in TVR.Interventional Cardiology
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Introduction: Percutaneous mitral valve repair using Mitraclip has recently emerged
as an alternative to surgery for the treatment of severe mitral regurgitation (MR). The
purpose of this study is to describe the initial experiences in Turkey with the MitraClip
system.
Methods: Twenty patients with severe MR underwent treatment with the MitraClip in
our center. Preoperatively, all the patients underwent a standardized protocol, which
included transesophageal echocardiography (TEE), angiography and evaluation of the
surgical risk.With the patient under general anaesthesia and using ﬂuoroscopic and TEE
guidance, the MitraClip device was introduced into the left atrium via the transfemoralJACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAvenous route and transseptal puncture. The MitraClip system was directed towards the
origin of the regurgitant jet and advanced into the left ventricle. The clip was retracted
until both leaﬂets were grasped and then closed to coapt the mitral leaﬂets. Device
success was deﬁned as placement of 1 or more MitraClip with reduction of MR to2+.
Results: From July 2012 to June 2013, 20 patients with severe MR with a mean age of
62.4 12.6 years (15 males and 5 females; mean logEuroScore 24.111, mean LVEF
26.110.3%) were treated with the MitraClip. Of the 20, 18 (90%) had functional MR
(ischaemic in 14 patients; dilated cardiomyopathy in 6 patients), one had papillary
muscle rupture due to acute myocardial infarction and the other had spontaneous
papillary muscle rupture. Before the procedure, average left ventricular ejection
fraction, left ventricular diastolic and systolic diameters and systolic pulmonary
pressure were 26.110.3%, 649 mm, 54 11 mm and 6218 mmHg, respectively.
Acute procedural success rate was 90% (n¼18). In two patients (10%), we were
unable to grasp the leaﬂets and no clip was deployed. Fifteen patients (75%) received
one device, 3 patients (6%) received two devices. The clip was implanted in the
central portion of the valve in 16 (80%) of patients. In two cases (10%), the clip was
implanted in the lateral scallops. Post-procedural MR severity was reported as MR
2+ in 90% of patients, with 44% of all patients achieving MR 1+. The procedural
mortality was 0%. No patient underwent emergency cardiac surgery for a failed clip
implantation. Cerebrovascular event, acute myocardial infarction, clip detachment or
embolization and site bleedings did not occur in any patients. In only one case,
immediately after the guide catheter removal from the interatrial septum, TEE
demonstrated a mobile thrombus seemed to be attached to the interatrial septum at the
septal puncture site. The patient was managed with anticoagulation because of the
high-risk nature of surgery. The TEE performed on the 5th postoperative day
demonstrated no thrombus. The median device time was 100 minutes.
Conclusion: Our initial results shows that MitraClip could be safe, feasible and
effective treatment in severe MR.
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Aims: Edge-to-edge repair of mitral regurgitation (MR) with the MitraClip system is
increasingly applied in advanced heart failure. Our objective was to compare
outcomes in patients with moderate and severe systolic heart failure.
Methods-Results: Between February 2010 and July 2012, 121 patients with MR of at
least grade 3+ and ameanEuroSCORE II of 10.6%underwentMitraClip implantation.
39 had a left ventricular ejection fraction (LVEF) of 30% (group A) and 82 of >30%
(group B). Procedural success was comparable in both groups (100% vs 95.2%) with
multiple (>2) clip implantation in 34% respectively 25% of patients. At 12 months
absolute reduction ofMRgrade (2.3 vs. 2.2) and relative reduction ofmitral valve oriﬁce
area (48% vs 42%) was also comparable. LVEF parameter and NYHA class had
improved signiﬁcantly 12 months after MitraClip treatment in both groups compared to
baseline (Figure 1). In-hospital mortality was low in both groups (2.6% vs 2.4%) but
there was a strong trend for higher 12-month mortality in group A (34 % vs 18 %,
p¼0.05) with no signiﬁcant difference in the overall rate of major adverse
cerebrovascular and cardiac events (36.8% vs 28.9%, p¼0.38). On multivariate
analysis MR grade after repair was the strongest predictor of mortality (OR 2.121,
95% CI 1.095-4.109) whereas systolic impairment was no independent predictor.
Conclusion: Percutaneous mitral valve repair led to comparable symptomatic
improvement in patients with moderately or severely reduced LV function. LV-EF <
30% was no independent predictor of short term mortality which was mainly governed
by residual MR after repair.LS C43
